9 month old unimmunized child .
catch-up immunization schedule unimmunized 9 month old infant IAP 2026
IAP catch-up vaccination schedule 9 month unimmunized child India 2025 2026
https://babynama.com/guides/vaccination
| Vaccine | Reason |
|---|---|
| Rotavirus (RV) | Cannot start after 15 weeks; maximum age for final dose is 8 months. Permanently missed. |
| Birth dose BCG | Give now if not given (still beneficial - some protection) |
| Birth dose OPV-0 | Give OPV now as part of the series |
| Vaccine | Dose | Notes |
|---|---|---|
| BCG | 1 dose | If not previously given at birth |
| DTwP/DTaP | Dose 1 (primary series) | Start the 3-dose primary series |
| IPV | Dose 1 | Start the series |
| Hib | Dose 1 | Start the series |
| Hepatitis B | Dose 1 | Start the 3-dose series (0, 1, 6 month schedule) |
| PCV (Pneumococcal) | Dose 1 | Start the series |
| OPV | Dose 1 | Oral, can give alongside IPV |
| MMR | Dose 1 | 9 months is the IAP-recommended age for MMR-1; give now |
| TCV (Typhoid Conjugate) | Dose 1 | IAP recommends at 9-12 months |
| Vaccine | Dose | Notes |
|---|---|---|
| DTwP/DTaP | Dose 2 | Min interval: 4 weeks from Dose 1 |
| IPV | Dose 2 | Min interval: 4 weeks from Dose 1 |
| Hib | Dose 2 | Min interval: 4 weeks from Dose 1 |
| Hepatitis B | Dose 2 | Min interval: 4 weeks from Dose 1 |
| PCV | Dose 2 | Min interval: 4 weeks from Dose 1 |
| Vaccine | Dose | Notes |
|---|---|---|
| DTwP/DTaP | Dose 3 | Completes primary series |
| IPV | Dose 3 | Completes primary series |
| Hib | Dose 3 | Completes primary series |
| PCV | Dose 3 | Completes primary series |
| Vaccine | Dose | Notes |
|---|---|---|
| Hepatitis B | Dose 3 | At least 8 weeks after Dose 2, and at least 16 weeks after Dose 1 |
| MMR | Dose 2 | At least 4 weeks after MMR-1; IAP recommends MMR-2 at 15 months |
| Varicella | Dose 1 | IAP recommends starting at 12 months |
| Hepatitis A | Dose 1 | IAP recommends starting at 12 months |
| PCV Booster | Booster | At 15 months |
| Vaccine | Dose | Notes |
|---|---|---|
| DTwP/DTaP Booster 1 | Booster | 6 months after completing primary series |
| IPV Booster | Booster | |
| Hib Booster | Booster | |
| Varicella | Dose 2 | At least 3 months after Dose 1 |
| Hepatitis A | Dose 2 | 6 months after Dose 1 |
| Vaccine | Catch-Up Possible? |
|---|---|
| BCG | Yes |
| Hepatitis B | Yes (3-dose series) |
| DTwP/DTaP | Yes (3 doses + boosters) |
| IPV/OPV | Yes |
| Hib | Yes |
| PCV | Yes |
| Rotavirus | No - missed permanently |
| MMR | Yes (give now at 9 months) |
| Typhoid (TCV) | Yes |
| Varicella | Yes (from 12 months) |
| Hepatitis A | Yes (from 12 months) |
| Influenza | Yes (2 doses first time) |
According to National immunization schedule
India National Immunization Schedule NIS UIP catch-up unimmunized child 2024 2025
https://prod-cdn.preprod.co-vin.in/uwin-prod/pdf/National+Im…
| Vaccine | NIS Age | Route | Dose | Site |
|---|---|---|---|---|
| BCG | Birth (up to 1 year) | Intra-dermal | 0.1 ml | Left upper arm |
| Hepatitis B birth dose | Within 24 hours of birth | IM | 0.5 ml | Anterolateral thigh |
| OPV-0 | Birth (within 15 days) | Oral | 2 drops | Oral |
| OPV 1, 2, 3 | 6, 10, 14 weeks | Oral | 2 drops | Oral |
| Pentavalent 1, 2, 3 (DPT + Hib + HepB) | 6, 10, 14 weeks | IM | 0.5 ml | Anterolateral thigh |
| fIPV 1, 2 | 6 and 14 weeks (fractional) | Intra-dermal | 0.1 ml | Right upper arm |
| RVV (Rotavirus) | 6, 10, 14 weeks | Oral | 3 drops | Oral |
| PCV 1, 2 | 6 and 14 weeks | IM | 0.5 ml | Anterolateral thigh |
| MR-1 | 9-12 months | Sub-cutaneous | 0.5 ml | Right upper arm |
| JE-1 | 9-12 months | Sub-cutaneous | 0.5 ml | — |
| PCV Booster | 9-12 months | IM | 0.5 ml | Anterolateral thigh |
| fIPV-3 | 9-12 months | Intra-dermal | 0.1 ml | Right upper arm |
| Vitamin A 1st dose | 9 months | Oral | 1 lakh IU | Oral |
*JE vaccine only in endemic/selected districts.
| Vaccine | Action | Notes |
|---|---|---|
| BCG | Give now | NIS permits up to 1 year of age |
| OPV | Start series (Dose 1) | OPV can be given till 5 years |
| Pentavalent-1 (DPT+Hib+HepB) | Start series (Dose 1) | Can be given till 1 year of age |
| fIPV | Dose 1 (fractional) | 0.1 ml ID, right upper arm |
| RVV (Rotavirus) | Dose 1 | ⚠️ NIS permits RVV up to 1 year under UIP - this is different from IAP; give now if < 1 year |
| PCV | Dose 1 | Start series |
| MR-1 | Give now | This is the scheduled age (9 completed months) |
| JE-1 | Give now | Only in endemic districts |
| Vitamin A | 1st dose (1 lakh IU oral) | Due at 9 months |
| Vaccine | Action |
|---|---|
| Pentavalent-2 | Dose 2 (4-week interval from Dose 1) |
| OPV-2 | Dose 2 |
| RVV-2 | Dose 2 |
| Vaccine | Action |
|---|---|
| Pentavalent-3 | Dose 3 - completes primary series |
| OPV-3 | Dose 3 |
| RVV-3 | Dose 3 |
| fIPV-2 | 2nd fractional IPV dose (at least 8 weeks after first fIPV) |
| PCV-2 | Dose 2 |
| Vaccine | Action |
|---|---|
| PCV Booster | Give after completing 2 primary PCV doses |
| fIPV-3 | 3rd fractional dose at 9-12 months (as per NIS schedule) |
| Vaccine | Action |
|---|---|
| MR-2 | 2nd dose (at least 4 weeks after MR-1) |
| JE-2 | 2nd dose (endemic districts only) |
| DPT Booster-1 | First booster |
| OPV Booster | Booster dose |
| Vitamin A | 2nd dose (2 lakh IU), then every 6 months till 5 years |
| Point | Detail |
|---|---|
| Rotavirus window (NIS) | Under NIS/UIP, RVV is permitted till 1 year of age - unlike IAP which restricts it to < 8 months. So this child can still receive RVV under government schedule. |
| Pentavalent | NIS uses Pentavalent (DPT + Hib + HepB combined) - given till 1 year of age |
| fIPV | Government schedule uses fractional (intradermal) IPV - 0.1 ml ID, not full 0.5 ml IM |
| Hepatitis B | Covered within Pentavalent - no separate HepB doses needed under NIS |
| No Varicella/HepA/TCV/MMR | These are NOT part of NIS - they are IAP-only (private) vaccines |
| MR vs MMR | NIS provides MR (Measles + Rubella, no Mumps). MMR requires a private clinic. |
| All free | All NIS vaccines are free at government ASHA/ANM/health center |
Source: National Immunization Schedule - Government of India (UIP) | Park's Textbook of Preventive & Social Medicine, Table 43 (NIS 2020)